safinamide (xadago) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Safinamide (FCE 26743, NW 1015, PNU 151774, PNU 151774E, trade name Xadago) combines potent, selective, and reversible inhibition of MAO-B with blockade of voltage-dependent Na+ and Ca2+ channels and inhibition of glutamate release. Safinamide is under development with Newron, Zambon and Meiji Seika Pharma for the treatment of Parkinson's disease. Safinamide has been launched in the EU, Iceland and Liechtenstein. Safinamide was well tolerated and safe in the clinical development program that demonstrated the amelioration of motor symptoms and OFF phenomena by safinamide when combined with dopamine agonists or levodopa.   NCATS

Chemistry

  • SMILES: C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(=O)N
  • InChIKey: NEMGRZFTLSKBAP-LBPRGKRZSA-N
  • Mol. Mass: 302.35
  • ALogP: 2.37
  • ChEMBL Molecules:
    safinamide  
    safinamide mesylate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$1.3529 - $2.7058

United States

$20.8900 - $29.0395
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2-(4-(3-fluorobenzyloxy)benzylamino)propionamide | emd 1195686 | emd-1195686 | fbap methanesulfonate | fce 26743 | fce-26743 | fce 28073 | fce-28073 | nw-1015 | pnu 151774e | pnu-151774e | (s)-2-((4-(3-fluorobenzoxy)benzyl)amino)propanamide | safinamide | safinamide mesilate | safinamide mesylate | safinamide methanesulfonate | safinimide | xadago

Organizations (82)

Research & Development (77)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (1)


 

Parkinson Disease

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Dyskinesia, Drug-Induced (Phase 3)

Healthy Volunteers (Phase 1)

Kidney Failure, Chronic (Phase 1)

Liver Diseases (Phase 1)

Multiple System Atrophy (Phase 2)

Parkinson Disease ()

Overview

  • Highest Phase: Phase 4
  • # of Trials: 24
  • # of Trial Organizations: 77

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue